Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
A next-generation CD33-directed ADC for AML
Is venetoclax in combination with low-dose cytarabine a safe regimen for the treatment of AML?
ASH 2017 President’s meeting highlights